Nautilus Biotechnology, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Nautilus Biotechnology reported a quarterly adjusted loss of 12 cents per share, narrower than the year-earlier loss and better than the 14 cents analysts expected. Revenue was $234.00 thousand versus $206.25 thousand expected, and the quarterly loss was $15.64 million.

Confirmed

Global impact / market context

A smaller loss than expected plus revenue above estimates suggests the company is spending less than feared while still generating sales, which can reduce how much cash it must raise later. That matters for a loss-making biotech firm dependent on outside funding.

Analyst inference

Analysts rate the shares a strong buy, with four buy ratings and no holds or sells, and a median 12-month price target of $4.00, about 39% above the $2.44 last close. The stock rose 71.8% this quarter and 25.1% this year.

Analyst inference

What to watch

1. The mean earnings estimate stayed unchanged over the last three months, and analysts made no earnings estimate revisions in the last 30 days covering the company. Confirmed
2. Investors could watch whether Nautilus turns its revenue into steady growth and narrows losses further, since continued losses may require raising borrowed or investor money. Proposed
3. The $4.00 median price target sits about 39% above the $2.44 last close, so the gap between analyst expectations and the share price is a key measure of investor positioning. Analyst inference

Evidence

• Original source link unavailable